Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
February 23, 2004
- Notification on Reuse of Implantable Medical Materials
February 23, 2004
- Pfizer Japan to Build Up Ophthalmology Business in Japan
February 23, 2004
- DIAGNOSTIC NEWS IN BRIEF
February 23, 2004
- Takeda's MRs Are Best to Solve Doctors' Problems: Moss Survey
February 23, 2004
- Efficiency of NHI Price System Increased: Dr Yazaki
February 23, 2004
- BUSINESS NEWS IN BRIEF
February 23, 2004
- CORPORATE ROUNDUP NEWS IN BRIEF
February 23, 2004
- 1st 3 Qtrs Business Results
February 23, 2004
- Chugai Enhancing R&D Efficiency via Information Sharing
February 23, 2004
- RESEARCH & DEVELOPMENT NEWS IN BRIEF
February 23, 2004
- PRESS SEMINAR
February 23, 2004
- REGULATORY NEWS IN BRIEF
February 16, 2004
- New Glucose Chip Requires Very Small Amount of Blood: Dr Karube of TUT
February 16, 2004
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
February 16, 2004
- Gene Therapy for Alzheimer's Disease Successful in Mice
February 16, 2004
- Taxotere, Cisplatin Combination Therapy Prolongs Survival: Aventis
February 16, 2004
- Tsumura's Herbal Drug Mixture Promotes Hair Growth
February 16, 2004
- BULLETIN
February 16, 2004
- 1st 3 Qtrs Business Results
February 16, 2004
ページ
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…